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Abstract
Background: Depression and obesity are significant global health concerns that commonly occur together. An
integrated group cognitive behavioural therapy program was therefore developed to simultaneously address
comorbid depression and obesity.
Methods: Twenty-four participants (63% women, mean age 46 years) who screened positively for depression with a
body mass index ≥25 were recruited from a self-referred general population sample. The group therapy program
(10 two-hour weekly sessions) was examined in a single-arm, before-after pilot trial, conducted in a behavioural
health clinic in Adelaide, Australia. Primary outcomes included survey and assessment-based analyses of depression,
anxiety, body image, self-esteem, and weight (kg), assessed at four time-points: baseline, post-intervention, three-
months and 12-months post program. Eighteen participants (75%) completed the program and all assessments.
Results: Significant improvements in depression, anxiety, self-esteem and body shape concern scores, several
quality of life domains, eating behaviours and total physical activity (among others) – but not weight – were
observed over the course of the trial.
Conclusions: Results from this pilot trial suggest that combining interventions for depression and obesity may be
useful. Further development of the program, particularly regarding the potential for physical health benefits, and a
randomised controlled trial, are warranted.
Trial registration: Trial registration: ANZCTR, ACTRN12617001079336, 13 July 2017. Retrospectively registered after
date of the first consent (6 July 2017), but before the date of the first intervention session (20 July 2017).
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Background
Depression and obesity are significant global health con-
cerns. Depression is recognised as the single greatest
contributor to global disability, accounting for 7.5% of
all YLD (Years Lived with Disability), and afflicting over
300 million people worldwide [1]. One million Austra-
lian adults experience depression each year, with an
estimated one in six people being diagnosed at some
point during their lifetime [2]. People with depression
are at increased risk of developing other mental health
problems such as anxiety, substance abuse and other
mood disorders [3]. Interpersonal relationships are often
impaired, leading to isolation, reduced social and emo-
tional health, and decreased productivity. Depression
can also significantly impact physical health and is asso-
ciated with reduced immune function and increased in-
cidence of cardiovascular disease, type 2 diabetes
mellitus, stroke and Parkinson’s disease, among others
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[4–7]. Weight gain is commonly experienced, and as
outlined below, there are clear reciprocal links between
depression and being overweight or obese [8].
Obesity is typically assessed using the Body Mass
Index [BMI = weight (kg)/height (m)2] (although more
precise definitions of obesity may be preferred at the in-
dividual level [9]). A BMI of 25–29.9 is classified as over-
weight, and a BMI ≥ 30 as obese [10]. Obesity rates have
increased substantially over the past several decades.
Current estimates suggest that nearly 30% of the world’s
population is overweight or obese, with even higher
numbers in developed countries such as in Australia
(64%) and the United States (68%) [11, 12]. For ease of
reference, herein “obese” or “obesity” will comprise both
clinical categories (overweight and obesity, i.e. BMI ≥
25). Explanations for obesity’s rising prevalence include
sedentary lifestyles and poor diets, combined with bio-
logical, genetic and psychological vulnerabilities [8, 13–
15]. As with depression, obesity is associated with
greater risk of health problems including cardiovascular
disease, type 2 diabetes mellitus, stroke, high blood pres-
sure and certain cancers [16, 17]. Obesity can also nega-
tively impact a range of psychosocial factors such as
sociability, willingness to exercise, body image and self-
esteem [15].
Separately, depression and obesity are significant prob-
lems, but both may be most refractory when comorbid,
as commonly occurs [18, 19]. Obesity at baseline has
been associated with a 1.55-fold increase in depression
incidence at follow-up, and depression at baseline has
been associated with a 1.58-fold increased risk of devel-
oping obesity [8, 20]. This reciprocal relationship may be
due to multiple biological, cognitive and/or behavioural
feedback loops that likely drive the pathology of both
conditions such that obesity begets depression, leading
to greater obesity (and vice versa) [19, 21]. Both are evi-
denced to be multigenic and multifactorial disorders.
Underlying biological mechanisms common to both de-
pression and obesity include, at minimum, endocrine
and hypothalamic–pituitary–adrenal (HPA) axis dysreg-
ulation; neuroimmune and neuroinflammatory pathways;
metabolic, bioenergetic, and oxidative stress pathways;
neurogenesis and neuroplasticity; and neurotransmitter
disruptions [19, 21, 22]. Behaviourally, a person who ex-
periences depression may reduce their activity and in-
crease their intake of comfort foods, resulting in weight
gain and elevated cortisol, which in turn promotes appe-
tite (especially for less healthy foods) and further weight
gain [19, 21, 22]. Antidepressants may also be associated
with increased appetite and weight gain, particularly in
the context of unhealthy lifestyles [23, 24]. Cognitively,
negative thinking patterns and low self-worth contribute
to distress and unhelpful behavioural responses. Like-
wise, a person struggling with obesity may experience
body dissatisfaction and social stigma, which may lead to
distress, reduced self-esteem and depression, particularly
when these symptoms are endured over long periods.
Thus, these reciprocal links act to mutually reinforce
both conditions [19, 21].
For these reasons, there is significant need for inte-
grated therapies that can effectively treat depression and
obesity together. Here we present a preliminary quasi-
experimental (single-arm) before-after pilot trial of a
newly developed group-based psychological intervention
program for people with depression and comorbid obes-
ity, that incorporates elements of both cognitive behav-
ioural therapy (CBT) as well as some mindfulness and
acceptance techniques/strategies. We hypothesised that
participants completing this novel group psychological
intervention program would exhibit 1) reduced levels of
depression and anxiety (i.e. better mental health), 2) in-
creased healthy eating habits, physical activity, sleep
quality and stress management capacity (i.e. more
health-positive behaviours), 3) fewer weight-related
negative cognitions (i.e. increased self-esteem and body
image positivity), and 4) weight loss, at post-intervention
and follow-up. The results of this pilot trial and implica-
tions for further development of this program and inte-
grative treatment of obesity comorbid with depression
are discussed.
Methods
Group therapy program protocol
Other studies have demonstrated the effectiveness of
psychological therapies for the treatment of depression
[25] and obesity (weight loss) [26] independently, but
few studies have endeavoured to treat them concur-
rently. To fill this gap, we developed a novel group ther-
apy program for simultaneously treating comorbid
depression and obesity within a single unified psycho-
logical intervention. The protocol incorporated a range
of cognitive-behavioural, acceptance and mindfulness
strategies that have been shown to be efficacious in the
treatment of both depression and obesity. The resulting
program consisted of 10 two-hour group sessions held
weekly at the South Australian Health and Medical
Research Institute (SAHMRI), co-facilitated by a
psychologist and a mental health professional. Each ses-
sion focused on a different topic, included reinforcement
of prior learning and allocated home-based practice. Key
topics covered in the program are outlined in
supplemental eTable 1.
Ethical considerations and trial registration
Ethics approval was granted by the Flinders University
Social and Behavioural Research Ethics Committee
(SBREC) in May 2017 (Project No. 7601), and the trial
was retrospectively registered with the Australian New
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Zealand Clinical Trials Registry (ANZCTR) (http://www.
anzctr.org.au) (registration submitted 13 July 2017; regis-
tration recorded 25 July 2017; trial number ACTR
N12617001079336), after the date of the first consent (6
July 2017), but before the date of the first intervention
treatment session (20 July 2017). The full trial protocol
is available here: (https://anzctr.org.au/Trial/Registra-
tion/TrialReview.aspx?ACTRN=12617001079336). All
participants were provided with a participation informa-
tion sheet and consent form prior to interview, and in-
formed written consent was obtained for study
participation. All research at SAHMRI adheres to the
Australian Government National Statement on Ethical
Conduct in Human Research (2007), which details sec-
tions on Scope, Methods, Recruitment, Collection and
management of data and dissemination of results [27].
Sampling and trial design
Participants were recruited from the general population
in Adelaide, South Australia by advertisement of the
study on local radio, the SAHMRI website and online
news media over a period of 3 months. Interested indi-
viduals were directed to a SAHMRI website to register,
after which they were contacted by phone for a brief
screen with one of the primary researchers. During the
telephone screening, potential participants were pro-
vided with an overview of the program, key trial aims,
and participation details, and they were asked whether
they could commit to the 10-week program for the spe-
cified dates. Eligibility was then assessed and a face-to-
face appointment to complete the initial (baseline)
assessment was arranged for those meeting inclusion
criteria.
Participants were assessed in four separate appoint-
ments at SAHMRI: baseline (i.e. within 2 weeks prior to
the start of the group therapy program); immediate
post-intervention (within 2 weeks of the program end-
ing); 3 months post-intervention (within 2 weeks of the
target date); and 12 months post-intervention (within 2
weeks of the target date). To maintain the small group
size required for group therapy [28], two cohorts of par-
ticipants completed the 10-week program at SAHMRI in
a single-arm before-after pilot study design (i.e. all par-
ticipants were subject to the same intervention), and the
results for all participants who completed the program
were analysed together. Completion of the program re-
quired participants to attend at least seven of the ten
sessions (70% attendance), in order for the effectiveness
of the program to be properly evaluated [29]. Consistent
with a per protocol analysis, those who did not meet this
criterion (70% attendance) were excluded from analysis.
The first group completed the 10-week program in July
– September 2017, and the second group in January –
March 2018.
Participants
Adults aged 18–65 years, with BMI ≥ 25 (i.e. overweight
or obese) and scoring ≥5 on the Patient Health Ques-
tionnaire (PHQ-9 – depression screening tool) [30] were
eligible to participate in the trial. Individuals with a
major systemic or physical illness that affected weight;
an uncontrolled thyroid disorder; an eating disorder di-
agnosed within the last twelve months; an uncontrolled
psychiatric or personality disorder; a problematic use of
alcohol or other substances; or intellectual impairment
or other cognitive deficits that could impair progress in
the group setting were excluded. Antidepressant medica-
tion use was allowed, however concurrent participation
in other forms of psychological therapy for depression
or obesity/weight management was not.
Measures
Sample characteristics
Demographic data (including age, sex, and cultural back-
ground) were collected via an initial survey at the first
assessment appointment. Use of antidepressant medica-
tion and presence of comorbid physical health problems
were also recorded.
Primary outcome measures
A range of primary outcome measures were adminis-
tered. Specifically, depression severity was measured
with the Hamilton Depression Scale (HAM-D), anxiety
with the Hamilton Anxiety Scale (HAM-A), self-esteem
with the Rosenberg Self-Esteem Scale (RSES), and body
image concerns with the Body Shape Questionnaire
(BSQ-34). Participant weight (kg) and height (cm) were
collected and BMI was calculated (kg/m2).
Secondary outcomes measures
Health-related quality of life was assessed by the RAND-
36 item Health Survey (SF-36), which measures quality
of life in eight domains, including physical functioning,
emotional wellbeing and general health. Physical activity
(including number of days, hours or minutes of total,
vigorous, moderate, and sedentary activity) was gauged
with the Global Physical Activity Questionnaire (GPAQ).
Nutritional intake was assessed with the Commonwealth
Scientific and Industrial Research Organisation (CSIRO)
Healthy Diet Score questionnaire, which provides a total
overall diet quality score as well as number of daily serv-
ings of different types of food and beverages (e.g. fruits
and vegetables, discretionary foods). Additional health
behaviours measured included eating behaviour (for ex-
ample, restrictive and emotional eating) with the Three
Factor Eating Questionnaire (TFEQ-R18), alcohol con-
sumption with the Alcohol Use Disorders Identification
Test (AUDIT), and sleep quality (including various sleep
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components) with the Pittsburgh Sleep Quality Index
(PSQI).
Additional physical measurements were also collected:
specifically, waist circumference (cm), hip circumference
(cm), blood pressure (systolic and diastolic mm Hg), and
pulse rate (beats per minute). Waist-to-hip and waist-to-
height ratios were calculated. Participants were also
asked to rate their current level of mental health and
physical health, as well as their readiness to change and
confidence in making the changes required to improve
their health.
Primary and secondary outcome measures are de-
scribed in greater detail in the Supplemental materials.
Score ranges and clinical interpretations are displayed in
Table 2.
Evaluation of treatment acceptability
At the end of their 10-week group therapy program,
participants completed a short evaluation form which
asked them to rate their experience of the interven-
tion across 22 items (e.g., each session’s quality, early
experiences in the program, location, timing, group
dynamics) on a 5-point scale from 1 (very poor) to 5
(very good).
Statistical analysis
Recommended minimum sample sizes for pilot studies
of this nature, which are in themselves intended to de-
termine sample sizes required to achieve appropriate
statistical power and suitability for future randomised
controlled trials (RCTs), is n = 12 [31], plus 15% for
non-parametric tests [32] (i.e. n = 14). Our sample size
exceeded that value and provided adequate power.
Descriptive statistics and frequencies were generated on
baseline data to describe the characteristics of the popu-
lation at intake. Variables at all four time-points were
inspected for outliers and distribution characteristics to
check assumptions for conducting repeated measures
analyses. Several variables violated assumptions of nor-
mality and outliers. Therefore, the non-parametric
Friedman test was used to investigate changes in
outcomes over the four time-points (baseline, post-
intervention, 3-month follow-up and 12-month follow-
up): p < .05 was considered significant. Follow-up
pairwise comparisons were performed to determine
where the significant changes occurred.
Results
Sample characteristics at baseline
The CONSORT-type diagram for flow of participants
through the trial is shown in Fig. 1. A total of 24
participants were recruited to the program across two
pilot groups. Of these, 18 completed the program, at-
tending an average of 8.8 out of the 10 sessions.
Three individuals provided reasons for declining/ceas-
ing the program (“too many commitments” – dropped
out before session one, “not comfortable with other
group members” – dropped out after session one, and
“dealing with a relationship break-up” – dropped out
after session five). The remaining three participants
did not respond to requests for a withdrawal reason.
Sample characteristics of participants are shown in
Table 1.
Baseline (pre-intervention) assessment
Prior to starting the program, the 24 initial partici-
pants (i.e. pre-dropouts) reported moderate to severe
levels of depression, mild to moderate levels of anx-
iety, normal self-esteem, and moderate concerns with
body shape. On average, participants’ BMI was within
the moderately obese range (obese class II). Their
mean score on the CSIRO Healthy Diet questionnaire
was below the Australian national average of 59, and
their reported average daily servings of fruit and
vegetables were below national recommendations.
Participants were not meeting the recommended
Fig. 1 CONSORT diagram depicting flow of participants through trial
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amount of physical activity per week, and sleep qual-
ity was poor. Table 2 displays participants’ mean
scores at baseline for primary (and some secondary)
outcome variables.
Baseline scores for additional secondary outcome
variables (e.g. participants’ subjective ratings of their
own mental and physical health, readiness to change,
and confidence to make the changes required, as
well as other physical, quality of life, and health
behaviour data) are summarised in supplemental
eTable 2, for all 24 subjects prior to the start of the
program (pre-dropouts).
Program outcomes
There were significant changes for multiple primary and
secondary outcome measures over the course of the trial,
including participant self-ratings of health, depression,
anxiety, body shape concerns, self-esteem, several di-
mensions of quality of life and two types of health be-
haviours (Table 3). Specifically, participants’ depression
scores declined significantly between baseline and post-
intervention, and this improvement was maintained at
three-month and 12-month follow-ups (p = .001, <.001,
and < .001, respectively). Likewise, there was a signifi-
cant decrease in anxiety scores between baseline and
post-intervention (p = .049), with the improvement
remaining significant at both three-month (p = .004)
and 12-month follow-up (p < .001). Participants’ body
shape concerns declined over the course of the trial:
the change between baseline and post-intervention
was not significant, but the reduction from baseline
was statistically significant at three-month(p = .018)
and 12-month follow-up(p < .001). These three not-
able findings are illustrated in Fig. 2. Self-esteem in-
creased over the trial period, but the change was only
statistically significant between baseline and 12-month
follow-up (p = .006).
Participants’ self-rated mental health did not change
significantly between baseline and post-intervention but
was significantly improved at three-month and 12-
month follow-up (p = .040 and .027, respectively). Self-
rated physical health only improved between baseline
and 12-month follow-up (p = .018). With respect to di-
mensions of quality of life, participants’ emotional well-
being showed no change at the end of the program but
was improved versus baseline at both three-month
(p = .032) and 12-month follow-up (p < .001). Similarly,
energy/fatigue showed no change post-intervention,
but was improved versus baseline at three-month and
12-month follow-up (p = .039 and < .001, respect-
ively). General health improved between baseline and
post-intervention (p = .030), and this was maintained
at 12-month follow-up (p = .001). Participants’ role
limitations due to physical health problems signifi-
cantly improved over the course of the study; how-
ever, post-hoc comparisons were non-significant.
Role limitations due to emotional problems also im-
proved, but only between baseline and 12-month
follow-up (p = .003).
Regarding health behaviours, emotional eating behav-
iour decreased between baseline and post-intervention
(p = .022) and remained significantly reduced 12months
later (p = .018). Cognitive restraint did not change
post-intervention or at three-month follow-up but
had increased at 12-month follow-up relative to base-
line (p < .001). Participants’ total hours of physical ac-
tivity per week significantly increased (p = .036), most
Table 1 Sample characteristics of trial sample at baseline (n =
23) a
Count (%)




Single / never married 5 (20.8%)
Divorced / separated 3 (12.5%)
Married / de facto 15 (62.5%)
Antidepressant use (current) 15 (62.5%)
Physical health comorbidities 9 (38%)
Smoking status





Aboriginal / TSI 1 (4.2%)
Indian 1 (4.2%)
Education
Some school 3 (12.5%)
High school graduate 3 (12.5%)
Technical / vocational training 8 (33.3%)
Bachelor’s degree 6 (25%)




Salaried income 11 (45.8%)
Unable to work 3 (12.5%)
Retired 1 (4.2%)
Studying 2 (8.3%)
Age (mean years) b46.39 (10.08), range 18–64
aNB: demographic data (except for sex) missing for one participant
bNB: Refers to M (SD), all other data refer to n(%)
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notably between baseline and 12-month follow-up
(p = .010).
Additional secondary and non-significant (p > .05) out-
comes are shown in eTable 3 in the Supplemental mate-
rials. Other domains of quality of life and numerous
health behaviours did not change throughout the trial.
There were no significant changes in participants’ weight
or other physical measurements (e.g. waist-to-height ratio)
between baseline and post-intervention or at three-month
or 12-month follow-up. Moreover, there were no signifi-
cant changes in participants’ nutritional intake or sleep.
However, the results of preliminary analyses conducted
immediately post-intervention showed significant im-
provements between baseline and post-intervention in un-
controlled eating behaviour, discretionary food intake, and
overall sleep problems – see eTable 4 in Supplemental
materials – but these changes were not statistically signifi-
cant when the comparison was made across all four time-
points in the main analysis (Table 3).
Evaluation of treatment acceptability
Quantitative feedback gathered from participants at the
end of the final session of the group therapy program
was predominantly positive with the majority providing
ratings of “good” to “very good” (eTable 5). The open-
ended qualitative feedback was also encouraging (refer
to eTable 6 for a sample). Participants were further given
the opportunity to provide verbal feedback to the other
group members and facilitators during the final session,
and this was overwhelmingly positive.
Discussion
This pilot study sought to examine the potential benefits
of a newly developed group-based psychological inter-
vention program for people with comorbid depression
and obesity. The main aims of the program were to help
people achieve better mental health, establish and/or in-
crease health behaviours, improve weight-related cogni-
tions, and facilitate weight loss. We also hoped that
focusing on overall mind and body health would lead to
improvements that were sustainable over the medium to
long-term. We found there was a significant reduction
in participants’ depression scores by program-end, with
many moving from the moderate/severe to normal (non-
clinical) ranges on the Hamilton Depression Scale
(HAM-D). Additionally, participants’ HAM-A anxiety
scores also decreased significantly, moving from the
mild/moderate to normal ranges. Importantly, improve-
ments in both variables were maintained at follow-up 3
months and 12 months after the intervention had ended.
The group therapy program therefore has considerable
potential to be effective in helping people enjoy better
mental health – one of its key aims.
There is also some evidence of improvements in
weight-related negative cognitions, with participants ex-
periencing a significant reduction in body shape con-
cerns by 3 months post-program (moving from
moderate to mild levels on the BSQ-34) – an improve-
ment which was maintained 12 months after the pro-
gram ended. For the target population, improving poor
body image is crucial, given its potential to be a trigger
Table 2 Mean outcome scores of trial sample at baseline (n = 24)
M (SD) [95% CI] (SE) [Omega] Score Range Clinical Interpretation
Psychological measures
Depression (HAM-D) 17.83 (6.59) [15.05–20.61] (1.34) [0.80] 0–52 > 17 moderate to severe
Anxiety (HAM-A) 15.96 (8.99) [12.16–19.75] (1.83) [0.85] 0–56 18–24 mild to moderate
Self-esteem (RSES) 22.98 (5.92) [20.48–25.48] (1.21) [0.92] 0–30 15–25 normal
Body image concerns (BSQ-34) 113.92 (34.53) [99.34–128.5] (7.05) [0.97] 34–204 111–140 moderate
Physical measurements
Weight (kg) 111.5 kg (18.50) [103.7–119.3] (3.78)
BMI (kg/m2) 39.39 (7.74) [36.11–42.66] (1.58) > 30 obese - class II
Waist-to-height ratio (cm/cm) .71 (.08) [.67–.74] (.02) >.63 for men, >.58 for women - morbidly obese
Health behaviours
CSIRO diet score (CSIRO) 47.75 (12.55) [42.32–53.18] (2.61) 1–100 below national average of 59
Vegetable intakea (CSIRO) 3.29 (3.41) [1.81–4.76] (0.71) < recommended 5
Fruit intakea (CSIRO) 1.14 (1.25) [.60–1.68] (0.26) < recommended 2
Total physical activityb (GPAQ) 2.10 (3.07) [.80–3.39] (0.63) [0.78] < recommended 2.5
Overall sleep problems (PSQI) 9.33 (3.91) [7.39–11.28] (0.92) (0.76) 0–21 > 5 poor sleep quality
a daily servings; b hours per week of moderate + physical activity. Abbreviations: HAM-D Hamilton Depression Rating Scale, HAM-A Hamilton Anxiety Rating Scale,
RSES Rosenberg Self-Esteem Scale, BSQ-34 Body Shape Questionnaire, CSIRO Commonwealth Scientific and Industrial Research Organisation, GPAQ Global Physical
Activity Questionnaire, PSQI Pittsburgh Sleep Quality Index. Statistics: M, SD, CI, SE, Omega are, respectively, Median, Standard Deviation, 95% Confidence Interval,
Standard Error, and McDonald’s Omega (ω)
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for unhelpful thoughts and unhealthy eating behaviours.
Our finding that body shape concerns were significantly
improved at both follow-up time-points (versus base-
line), but not immediately post-intervention, suggests
that changing perceptions about one’s body is a longer
process than the 10-week duration of the program. The
same may be true for shifting self-esteem, which demon-
strated an upward trend over time, and was significantly
improved at 12 months after the program ended.
Several other results support the notion that continued
improvement in program outcomes may be seen over
time. For example, several domains of quality of life (e.g.
emotional wellbeing and energy/fatigue) improved only
at follow-up (at three and 12months) but not immedi-
ately post-program. For many individuals, depression
and obesity are complex and chronic, so it makes sense
that a longer period for further practice and
reinforcement may be necessary for measurable changes
to occur. That said, the degree to which participants in
our trial continued practicing strategies or adhered
closely to their individual goals after post intervention is
unknown. Future studies could investigate ideal program
duration for this approach, and whether ongoing moni-
toring or follow-up sessions could enhance outcomes.
Significant improvements were seen in some health
behaviours (emotional eating, cognitive restraint, and
total physical activity; Table 3), and trends toward
improvements seen in others (uncontrolled eating
[p = .127] and discretionary food intake [p = .084]).
Physical activity, nutrition, and eating behaviours are
Table 3 Changes in medians of trial sample over time (outcomes from Friedman test) (n = 18)
Baseline Post-Intervention 3 Month
Follow-Up
12 Month Follow- Up
Median Median Median Median Range X2 df p-value ηρ2
Subjective ratings
Mental health 5 6 6.5 7.5 1–10 14.86 3 0.002 0.304
Physical health 3.5 5 4 6 1–10 11.3 3 0.01 0.217
Psychological measurements
Depression (HAM-D) 17 6.5 5 5.5 0–52 29.8 3 <.001 0.62
Anxiety (HAM-A) 15 6 5.5 4.5 0–56 24.09 3 <.001 0.507
Self-esteem (RSES) 22.5 27 26.5 26.75 0–30 11.63 3 0.009 0.201
Body shape concerns (BSQ-34) 117 108.5 102 94 34–204 22.23 3 <.001 0.388
Physical measurements
Weight (kg) 109.2 109.15 109.55 109.55 2.07 3 0.557 0.042
BMI (kg/m2) 36.97 37.79 37.37 37.11 1.86 3 0.602 0.039
Quality of life (SF-36)
Role limitations physical 62.5 62.5 75 100 0–100 8.48 3 0.037 0.105
Role limitations emotional 0 33.33 33.33 50 0–100 15.62 3 0.001 0.273
Energy / fatigue 15 15 30 42.5 0–100 16.13 3 <.001 0.519
Emotional wellbeing 44 44 68 74 0–100 32.47 3 <.001 0.57
General health 30 37.5 35 45 0–100 18.56 3 <.001 0.318
Health Behaviours
CSIRO diet score (CSIRO) 51.1 52.3 49.3 50.3 0–100 3.36 3 0.34 0.044
Discretionary food intakea (CSIRO) 6.12 3.61 3.56 2.73 6.66 3 0.084 0.292
Emotional eating (TFEQ-R18) 89 66.67 66.67 66.67 0–100 14.24 3 0.003 0.27
Uncontrolled eating (TFEQ-R18) 57.41 40.74 51.85 40.74 0–100 5.71 3 0.127 0.216
Cognitive restraint (TFEQ-R18) 27.78 38.89 36.11 47.22 0–100 21.47 3 <.001 0.344
Total physical activityb (GPAQ) 1.25 2.25 1.13 3.65 8.56 3 0.036 0.152
Sedentary activityb (GPAQ) 80.5 84 75.3 71.5 4.15 3 0.246 0.071
Overall sleep problems (PSQI) 10 7 9 8.5 0–21 2.74 3 0.434 0.086
a daily servings; b hours per week Abbreviations: HAM-D Hamilton Depression Rating Scale, HAM-A Hamilton Anxiety Rating Scale, RSES Rosenberg Self-Esteem
Scale, BSQ-34 Body Shape Questionnaire, CSIRO Commonwealth Scientific and Industrial Research Organisation, GPAQ Global Physical Activity Questionnaire, PSQI
Pittsburgh Sleep Quality Index, SF36 RAND 36-Item Health Survey 1.0; TFEQ-18 Three Factor Eating Questionnaire – Revised, ηρ
2 partial Eta Squared
Lores et al. BMC Psychology            (2020) 8:34 Page 7 of 11
associated with both physical and mental health,
hence the importance of establishing and strengthen-
ing healthy lifestyle habits in this target population.
The program could be further developed to build on
these improvements, including perhaps involvement
and co-facilitation by a dietician and/or exercise
physiologist.
Participants did not experience significant weight loss
immediately post-intervention or at follow-up assess-
ments three and 12 months later. A potentially
Fig. 2 Changes in median scores for trial sample over time. a Changes in depression scores over time. b Changes in anxiety scores over time. c
Changes in body shape concern scores over time
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confounding variable that may prevent weight loss
(particularly when accompanied by an unhealthy life-
style) is antidepressant therapy [23, 24], and 11 of
our 18 subjects were taking antidepressants during
the program. While our current trial was not de-
signed nor powered to answer the question of
whether antidepressant status affects weight loss dur-
ing/after the intervention, larger future trials can in-
corporate this question into their design. Preliminary
analyses do indicate, however, that improvements in
depression scores are similar even if cohorts are sub-
divided into medicated versus un-medicated groups;
that is, antidepressant status does not appear to be
responsible for the improvements in depression
scores. However, further validation in a larger study
is required. An active dietary intervention is also
likely to be needed if weight loss is the main desired
outcome.
The results of our pilot trial are similar to those re-
ported in other recent investigations of combined
treatment approaches. For example, one recent RCT
of 1025 individuals [33] found that a psychological
therapy focused on food-related behavioural activation
was associated with improved anxiety and depression
scores in overweight or obese adults over time, par-
ticularly when depression severity was higher at base-
line (although the treatment approach did not prevent
the development of major depressive disorder at 1
year follow-up). Weight loss and body weight percep-
tions were not reported in this study. In another, the
addition of a cognitive behavioural therapy (CBT)
component for depression (CBTD) to a behavioural
weight control (BWC) program resulted in some
weight loss, described as modest but less than that
typically seen with non-depressed patients in BWC
therapies (discussed in [34]). The combined approach
did not significantly augment weight loss versus BWC
therapy alone [34, 35]. Compared to our program, the
BWC + CBTD treatment incorporated more directive
and hands-on measures designed to achieve weight
loss (e.g. prescriptions for calorie intake/diet and
amount of weekly exercise). Nevertheless, together
our and others’ results [33–35] demonstrate both the
potential of these combined approaches and the diffi-
culties they inherently face, particularly in achieving
large and/or sustained weight loss and other health
benefits in depressed individuals. Further work to de-
velop these programs to more effectively achieve these
goals is required.
We acknowledge that there are limitations to this
pilot trial, the main one being that there was no con-
trol arm of ‘usual care’ or healthy controls for com-
parison purposes. We therefore cannot rule out the
possibility that psychological health may have
improved naturally over time. Future trials of this
program should include a control arm in order to ap-
propriately evaluate efficacy. In addition, a potential
confounding factor results from the fact that partici-
pants using antidepressants were not excluded from
the trial. However, improvements in depression scores
were found to be similar for medicated and un-
medicated sub-groups. A larger sample size in future
trials would also bolster confidence in the results.
Conclusions
Taken overall, the results of this pilot trial of a novel
group therapy program are promising and warrant
further development and evaluation of the interven-
tion. The current program targeting comorbid depres-
sion and obesity is perceived as useful and acceptable
by participants and has potential to improve health
outcomes, particularly psychological well-being. Fur-
ther refinement of the program to include additional
content on specific health-positive behaviours and
weight loss measures will now be completed. Larger
randomised controlled trials are also required to sub-
stantiate these preliminary findings and further exam-
ine potential improvements in physical health
outcomes.
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